Ahmad Syed Sayeed, Younis Kaiser, Philippe Jeandet, Aschner Michael, Khan Haroon
Department of Medical Biotechnology, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow, India.
CNS Neurol Disord Drug Targets. 2022;21(7):610-620. doi: 10.2174/1871527320666210811160007.
Alzheimer's Disease (AD) is a chronic neurodegenerative disease. It is clinically characterized by memory loss and intellectual decrease, among other neurological deficits. The etiology of AD is not completely understood but includes amyloid plaques and intracellular helical filaments as well as neurofibrillary tangles with hyperphosphorylated tau protein. AD is also associated with alterations in amyloid processing genes, such as PSEN1 or PSEN2 and APP. The modulation of the immune system, cholesterol metabolism, and synaptic vesicle endocytosis have all been shown to remediate AD. In this review, enzymes such as AChE, BuChE, β-secretase, γ-secretase, MAO, and RAGE are discussed as potential targets for AD treatment. The aim of this review was to address the molecular mechanisms as well as various genetic factors in AD etiology. The use of natural compounds against these targets might be beneficial for the management of AD.
阿尔茨海默病(AD)是一种慢性神经退行性疾病。其临床特征为记忆丧失和智力减退,以及其他神经功能缺损。AD的病因尚未完全明确,但包括淀粉样斑块、细胞内螺旋丝以及含有高度磷酸化tau蛋白的神经原纤维缠结。AD还与淀粉样蛋白加工基因的改变有关,如早老素1(PSEN1)、早老素2(PSEN2)和淀粉样前体蛋白(APP)。免疫系统调节、胆固醇代谢和突触小泡内吞作用均已被证明可改善AD。在本综述中,乙酰胆碱酯酶(AChE)、丁酰胆碱酯酶(BuChE)、β-分泌酶、γ-分泌酶、单胺氧化酶(MAO)和晚期糖基化终末产物受体(RAGE)等酶作为AD治疗的潜在靶点进行了讨论。本综述的目的是探讨AD病因中的分子机制以及各种遗传因素。使用针对这些靶点的天然化合物可能有助于AD的管理。